The efficacy and effects of Pomalidomide

Pomalidomide has been studied in a major study involving 455 adults with multiple myeloma whose disease did not improve or came back after previous treatment. Pomalidomide combined with low-dose dexamethasone is more effective than high-dose dexamethasone alone in delaying the progression of multiple myeloma.

Patients taking pomalidomide plus low-dose dexamethasone worsened after an average of 16 weeks, while those taking high-dose dexamethasone took an average of 8 weeks to worsen. A further study included 559 multiple myeloma patients who received at least one treatment, including lenalidomide, and whose disease worsened during or after their last treatment. Patients treated with pomalidomide, bortezomib and low-dose dexamethasone lived an average of 11.2 months before their disease worsened.

Pomalidomide, independently developed in China, has been launched domestically and has now entered the scope of medical insurance. The price of domestically produced Pomalidomide may be around RMB 4,000 per box, while the Turkish version sold overseas may be priced around RMB 15,000 per box (the price may fluctuate due to exchange rates), which is relatively expensive. There are also cheaper generic drugs produced in other countries overseas. The price of each box produced by a Lao pharmaceutical factory may be around a few hundred yuan (the price may fluctuate due to the exchange rate). The ingredients of foreign generic drugs, domestically produced drugs and foreign original drugs are basically the same. For more drug information and specific prices, please consult Yaode Medical Consultant.